Back to Browse Journals » International Journal of Women's Health » Volume 5

Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy

Authors Minkin MJ, Maamari R, Reiter S

Published Date March 2013 Volume 2013:5 Pages 133—139

DOI http://dx.doi.org/10.2147/IJWH.S41897

Received 20 December 2012, Accepted 1 February 2013, Published 15 March 2013

Mary Jane Minkin,1 Ricardo Maamari,2 Suzanne Reiter3

1Obstetrics, Gynecology, and Menopause, Temple Medical Center, New Haven, CT, 2Hormone Therapy, Novo Nordisk Inc, Princeton, NJ, 3Mid-County Health Center, Largo, FL, USA

Abstract: Up to half of all postmenopausal women will experience changes in the genitourinary tract induced by the hypoestrogenic state, collectively known as vaginal atrophy. Vaginally administered local estrogen therapy (LET) is the standard of care for symptoms of vaginal atrophy that do not respond to nonhormonal interventions. Several LET formulations are available, and choice of therapy is based largely on patient needs and preferences. This online survey of postmenopausal LET users was conducted to investigate reasons for switching to vaginal estradiol tablets from other formulations and to evaluate factors associated with patient preference for and compliance with use of LET. Data was analyzed from 73 respondents currently using estradiol vaginal tablets who have previously used the estradiol vaginal ring, estradiol vaginal cream, and/or conjugated estrogen vaginal cream. Patients in this survey rated vaginal symptoms of vaginal atrophy as being more bothersome than urinary symptoms. Respondents preferred their current treatment with the vaginal tablet to their previous treatment with a cream or ring. The preference for tablets over creams was mainly related to formulation and application rather than to any perceived safety issues. Tablets were perceived as efficacious, convenient, and neat to apply. The study participants also reported a longer duration of tablet use compared with creams or rings, and greater compliance with vaginal tablets than with vaginal cream. This study provides new insights into reasons for patient noncompliance with estrogen cream or ring therapy that can be used to maximize patient adherence with LET.

Keywords: vaginal atrophy, local estrogen therapy, estradiol, vaginal ring, vaginal tablet, vaginal cream, conjugated estrogen vaginal cream

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Biochemical characterization of the interactions between doxorubicin and lipidic GM1 micelles with or without paclitaxel loading

Leonhard V, Alasino RV, Bianco ID, Garro AG, Heredia V, Beltramo DM

International Journal of Nanomedicine 2015, 10:3377-3388

Published Date: 6 May 2015

Impact on growth and invasion of gastric cancer cell lines by silencing NEDD9

Zhang SS, Wu LH, Liu Q, Chen KS, Zhang XF

OncoTargets and Therapy 2015, 8:223-231

Published Date: 20 January 2015

Enhanced photodynamic leishmanicidal activity of hydrophobic zinc phthalocyanine within archaeolipids containing liposomes [Corrigendum]

Perez AP, Casasco A, Schilrreff P, Defain Tesoriero MV, Duempelmann L, Pappalardo JS, Altube MJ, Higa L, Morilla MJ, Petray P, Romero EL

International Journal of Nanomedicine 2015, 10:169-170

Published Date: 29 December 2014

Quantitative evaluation in combination with nonquantitative evaluation in early patellar cartilage osteoarthritis at 3.0 T

Zuo HD, Yao WW, Qu N, Yang SX, Wang JH, Cui XJ

Clinical Interventions in Aging 2014, 9:1133-1143

Published Date: 16 July 2014

Use of hormonal contraceptives to control menstrual bleeding: attitudes and practice of Brazilian gynecologists

Makuch MY, Osis MJD, Pádua KS, Bahamondes L

International Journal of Women's Health 2013, 5:795-801

Published Date: 27 November 2013

Ductal adenocarcinoma of the prostate: immunohistochemical findings and clinical significance

Sha JJ, Bo JJ, Pan JH, Zhang LH, Xuan HQ, Chen W, Li D, Wang ZL, Liu DM, Huang YR

OncoTargets and Therapy 2013, 6:1501-1506

Published Date: 24 October 2013

Novel oral contraceptive for heavy menstrual bleeding: estradiol valerate and dienogest

Rafie S, Borgelt L, Koepf ER, Temple-Cooper ME, Lehman KJ

International Journal of Women's Health 2013, 5:313-321

Published Date: 12 June 2013

In vitro biocompatibility of calcined mesoporous silica particles and fetal blood cells

Al Samri MT, Biradar AV, Alsuwaidi AR, Balhaj G, Al-Hammadi S, Shehab S, Al-Salam S, Tariq S, Pramathan T, Benedict S, Asefa T, Souid AK

International Journal of Nanomedicine 2012, 7:3111-3121

Published Date: 3 August 2012

HER2-positive male breast cancer: an update

Laura Ottini, Carlo Capalbo, Piera Rizzolo, et al

Breast Cancer: Targets and Therapy 2010, 2:45-58

Published Date: 4 October 2010